{"id":"brimonidine-0-1-alphagan-p","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Ocular hyperemia (redness)"},{"rate":"10-20","effect":"Ocular pruritus (itching)"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Allergic conjunctivitis"},{"rate":"5-10","effect":"Blurred vision"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine selectively binds to alpha-2 adrenergic receptors on the ciliary body and trabecular meshwork of the eye. This activation reduces the production of aqueous humor (the fluid inside the eye) and enhances its drainage through the uveoscleral pathway, thereby lowering intraocular pressure. The 0.1% formulation (Alphagan P) is optimized for topical ocular administration with improved tolerability.","oneSentence":"Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:31.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT01525173","phase":"PHASE4","title":"A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":137},{"nctId":"NCT00457795","phase":"PHASE4","title":"24-hour IOP-lowering Effect of Brimonidine 0.1%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-12","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":15},{"nctId":"NCT00440141","phase":"PHASE4","title":"Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alphagan® P"],"phase":"marketed","status":"active","brandName":"brimonidine 0.1% (Alphagan® P)","genericName":"brimonidine 0.1% (Alphagan® P)","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow in the eye. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}